Invasive pneumococcal infections and the impact of vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13). 2021 Report.

Key Points

  • In 2021, the overall incidence rate of invasive pneumococcal infections decreased, but the decline was less pronounced than in the previous year and varied by age group.

  • The incidence rate was highest and rising again among children under 2 years of age, though levels remained below those of 2019, before the onset of the COVID-19 pandemic.

  • Among those aged 65 and older, incidence rates remain among the highest, with a more moderate decrease compared to the previous year.

  • The majority of infections were caused by serotypes not included in the PCV13 vaccine (notably serotype 8 in adults and serotype 24F in children), as well as by serotype 3 (included in PCV13) in adults.

In relation to

Our latest news

news

Call for Applications for the Renewal of the Editorial Board of the Weekly...

news

Launch of the “Heating, Health, Buildings, and Urban Planning” Network:...

news

2026 “Sexual Behavior” Survey (ERAS) for men who have sex with men